Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2011

Open Access 01-12-2011 | Gastrointestinal Oncology

Viable Tumor Tissue Adherent to Needle Applicators after Local Ablation: A Risk Factor for Local Tumor Progression

Authors: Nikol Snoeren, Joost Huiskens, Arjen M. Rijken, MD, Richard van Hillegersberg, MD, Arian R. van Erkel, Gerrit D. Slooter, MD, Joost M. Klaase, MD, Petrousjka M. van den Tol, MD, Fibo J. W. Ten Kate, MD, Maarten C. Jansen, MD, Thomas M. van Gulik, MD

Published in: Annals of Surgical Oncology | Issue 13/2011

Login to get access

Abstract

Background

Local tumor progression (LTP) is a serious complication after local ablation of malignant liver tumors, negatively influencing patient survival. LTP may be the result of incomplete ablation of the treated tumor. In this study, we determined whether viable tumor cells attached to the needle applicator after ablation was associated with LTP and disease-free survival.

Methods

In this prospective study, tissue was collected of 96 consecutive patients who underwent local liver ablations for 130 liver malignancies. Cells and tissue attached to the needle applicators were analyzed for viability using glucose-6-phosphate-dehydrogenase staining and autofluorescence intensity levels of H&E stained sections. Patients were followed-up until disease progression.

Results

Viable tumor cells were found on the needle applicators after local ablation in 26.7% of patients. The type of needle applicator used, an open approach, and the omission of track ablation were significantly correlated with viable tumor tissue adherent to the needle applicator. The presence of viable cells was an independent predictor of LTP. The attachment of viable cells to the needle applicators was associated with a shorter time to LTP.

Conclusions

Viable tumor cells adherent to the needle applicators were found after ablation of 26.7% of patients. An independent risk factor for viable cells adherent to the needle applicators is the omission of track ablation. We recommend using only RFA devices that have track ablation functionality. Adherence of viable tumor cells to the needle applicator after local ablation was an independent risk factor for LTP.
Literature
1.
2.
3.
Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159–66.PubMedCrossRef
4.
Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach.” Cancer. 2003;97:3027–35.PubMedCrossRef
5.
Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery. 2002;132:605–11.PubMedCrossRef
6.
Vogl TJ, Straub R, Eichler K, et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology. 2002;225:367–77.PubMedCrossRef
7.
Llovet JM, Vilana R, Bianchi L, et al. Radiofrequency in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol. 2001;24:303–11.PubMed
8.
Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460–6.PubMedCrossRef
9.
Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12:1967–72.PubMedCrossRef
10.
Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol. 2004;14:2261–7.PubMedCrossRef
11.
Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246:559–65.PubMedCrossRef
12.
Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol. 2008;31:948–56.PubMedCrossRef
13.
Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197:728–36.PubMedCrossRef
14.
Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616–28.PubMedCrossRef
15.
Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–7.PubMedCrossRef
16.
Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17:684–92.PubMedCrossRef
17.
Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.PubMedCrossRef
18.
Lupo L, Panzera P, Giannelli G, et al. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429–34.
19.
Mahnken AH, Bruners P, Gunther RW. Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Dig Dis. 2009;27:148–56.PubMedCrossRef
20.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.PubMedCrossRef
21.
Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441–51.PubMedCrossRef
22.
van Duijnhoven FH, Jansen MC, Junggeburt JM et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006;13:651–8.PubMedCrossRef
23.
Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242:158–71.PubMedCrossRef
24.
Ohlsson B, Nilsson J, Stenram U, et al. Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours. Br J Surg. 2002;89:757–62.PubMedCrossRef
25.
Snoeren N, Jansen MC, Rijken AM, et al. Assessment of Viable Tumour Tissue Attached to Needle Applicators after Local Ablation of Liver Tumours. Dig Surg. 2009;26:56–62.PubMedCrossRef
26.
Beutler E. Glucose-6-phosphate dehydrogenase: new perspectives. Blood. 1989;73:1397–401.PubMed
27.
Van Noorden CJ. Histochemistry and cytochemistry of glucose-6-phosphate dehydrogenase. Prog Histochem Cytochem. 1984;15:1–85.PubMed
28.
Hennings L, Kaufmann Y, Griffin R, et al. Dead or alive? Autofluorescence distinguishes heat-fixed from viable cells. Int J Hyperthermia. 2009;25:355–63.PubMedCrossRef
29.
Allwork SP, Bentall HH. Usefulness of the phenomenon of histofluorescence in the identification of early myocardial necrosis. Cardiovasc Res. 1986;20:451–7.PubMedCrossRef
30.
Anderson CD, Lin WC, Beckham J, et al. Fluorescence spectroscopy accurately detects irreversible cell damage during hepatic radiofrequency ablation. Surgery. 2004;136:524–31.PubMedCrossRef
31.
Chopra P, Sabherwal U. Histochemical and fluorescent techniques for detection of early myocardial ischemia following experimental coronary artery occlusion: a comparative and quantitative study. Angiology. 1988;39:132–40.PubMedCrossRef
32.
Salinas-Madrigal L, Sotelo-Avila C. Morphologic diagnosis of acute tubular necrosis (ATN) by autofluorescence. Am J Kidney Dis. 1986;7:84–7.PubMed
33.
Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008;249:364–74.PubMedCrossRef
34.
Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.PubMedCrossRef
35.
Rodgers MS, Collinson R, Desai S, et al. Risk of dissemination with biopsy of colorectal liver metastases. Dis Colon Rectum. 2003;46:454–8.PubMedCrossRef
36.
Jones OM, Rees M, John TG, et al. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg. 2005;92:1165–8.PubMedCrossRef
37.
Lepetit-Coiffe M, Laumonier H, Seror O, et al. Real-time monitoring of radiofrequency ablation of liver tumors using thermal-dose calculation by MR temperature imaging: initial results in nine patients, including follow-up. Eur Radiol. 2010;20:193–201.PubMedCrossRef
38.
Jaskolka JD, Asch MR, Kachura JR, et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol. 2005;16:485–91.PubMed
39.
Pacella CM, Bizzarri G, Spiezia S, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. Radiology. 2004;232:272–80.PubMedCrossRef
40.
Jansen MC, Van HR, Chamuleau RA et al (2005) Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 31:331–47.PubMedCrossRef
Metadata
Title
Viable Tumor Tissue Adherent to Needle Applicators after Local Ablation: A Risk Factor for Local Tumor Progression
Authors
Nikol Snoeren
Joost Huiskens
Arjen M. Rijken, MD
Richard van Hillegersberg, MD
Arian R. van Erkel
Gerrit D. Slooter, MD
Joost M. Klaase, MD
Petrousjka M. van den Tol, MD
Fibo J. W. Ten Kate, MD
Maarten C. Jansen, MD
Thomas M. van Gulik, MD
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 13/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1762-8

Other articles of this Issue 13/2011

Annals of Surgical Oncology 13/2011 Go to the issue

Translational Research and Biomarkers

Transcriptional Factor Prox1 Plays an Essential Role in the Antiproliferative Action of Interferon-γ in Esophageal Cancer Cells

Breast Oncology

Office Ductoscopy for Surgical Selection in Women with Pathologic Nipple Discharge

Colorectal Cancer

Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

Endocrine Tumors

Risk Factors for Nonsynchronous Second Primary Malignancy and Related Death in Patients with Differentiated Thyroid Carcinoma

Healthcare Policy and Outcomes

Quality Improvement in Multidisciplinary Cancer Teams: An Investigation of Teamwork and Clinical Decision-Making and Cross-Validation of Assessments

Gynecologic Oncology

Is Neo-adjuvant Chemotherapy a “Waiver” of Extensive Upper Abdominal Surgery in Advanced Epithelial Ovarian Cancer?